Chronic GVHD is associated with inferior relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors

Bone Marrow Transplantation

Volumn 47, Issue 11, 2012, Pages 1474-1478

  Signori, A ^a   Crocchiolo, R ^a   Oneto, R ^b   Sacchi, N ^c   Sormani, M P ^a   Fagioli, F ^b   Rambaldi, A ^b   Ciceri, F ^b   Bacigalupo, A ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b Italian Group of Bone Marrow Transplantation (GITMO)   (Italy)

^c Italian Bone Marrow Donor Registry (IBMDR)   (Italy)

Author keywords

GVHD; HLA; multistate models; PBSC; RRD; transplant

Indexed keywords

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CONTROL; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK REDUCTION; TREATMENT OUTCOME; UNRELATED DONORS;

CHRONIC DISEASE; GRAFT VS HOST DISEASE; HUMANS; LIVING DONORS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; RISK FACTORS; SURVIVAL RATE; TISSUE DONORS;

EID: 84869092299     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.58     Document Type: Article

References (28)

1. Socié G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341: 14-21.
2. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graftversus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562. (Pubitemid 20069191)
3. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529-1533. (Pubitemid 11065939)
4. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720-1728. (Pubitemid 19133213)
5. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R et al. Graftversus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23: 1993-2003. (Pubitemid 46211379)
6. Kanda Y, Izutsu K, Hirai H, Sakamaki H, Iseki T, Kodera Y et al. Effect of graft-versushost disease on the outcome of bone marrow transplantation from an HLAidentical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate. Leukemia 2004; 18: 1013-1019. (Pubitemid 38714628)
7. Ringdén O, Shrestha S, da Silva GT, Zhang M-J, Dispenzieri A, Remberger M et al. Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplant 2012; 47: 831-837.
8. Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26: 577-584. (Pubitemid 351264351)
9. Krö ger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004; 10: 698-708. (Pubitemid 39272874)
10. Mohty M, Boiron JM, Damaj G, Michallet AS, Bay JO, Faucher C et al. Graft-versusmyeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 77-84. (Pubitemid 39022961)
11. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685-3691. (Pubitemid 32786281)
12. Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011; 117: 3214-3219.
13. Passweg JR, Zhang MJ, Rocha V, Kan F, Champlin RE, Isola LM et al. Donor characteristics affecting graft failure, graft-versus-host disease, and survival after unrelated donor transplantation with reduced-intensity conditioning for hematologic malignancies. Biol Blood Marrow Transplant 2011; 17: 1869-1873.
14. Ozawa S, Nakaseko C, Nishimura M, Maruta A, Cho R, Ohwada C et al. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Br J Haematol 2007; 137: 142-151. (Pubitemid 46474715)
15. Crocchiolo R, Ciceri F, Fleischhauer K, Oneto R, Bruno B, Pollichieni S et al. KHLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry. Bone Marrow Transplant 2009; 44: 571-577.
16. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
17. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217. (Pubitemid 10036817)
18. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 2011; 94: 496-509.
19. Kalbfleish JD, Prentice HM. The Statistical Analysis of Failure Time Data. New York: Wiley, 1980.
20. Cortese G, Andersen PK. Competing risks and time-dependent covariates. Biometr J 2010; 51: 138-158.
21. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multistate models. Stat Med 2007; 26: 2389-2430. (Pubitemid 46730255)
22. Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 2012; 119: 1599-1606.
23. Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. J Clin Oncol 2000; 18: 537-546. (Pubitemid 30078535)
24. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al. Graft-versushost disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003; 102: 470-476. (Pubitemid 36841962)
25. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355: 1231-1237. (Pubitemid 30184533)
26. Teshima T, Matsuo K, Matsue K, Kawano F, Taniguchi S, Hara M et al. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors. Br J Haematol 2005; 130: 575-587. (Pubitemid 43899762)
27. Mohty M, Labopin M, Balè re ML, Socié G, Milpied N, Tabrizi R et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Socié te Française de Greffe de Moelle et de Thérapie Cellulaire. Leukemia 2010; 24: 1867-1874.
28. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. Highresolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576-4583. (Pubitemid 351377826)